A daily stock analysis based on stock market today
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up

Vertex Pharmaceuticals (VRTX): Buy the Dip?

6/11/2021

 

​Key Points

  • Investors Continue with Optimism as The SEC Investigates Meme Stocks
  • Dick's Sporting Goods (DKS) and Best Buy (BBY) Are Solid Retailers with Undervalued Stocks
  • The 10% Drop in Vertex Pharmaceuticals (VRTX) May Mean a Buy-the-Dip Opportunity

​Overall Market

Investors Continue with Optimism as The SEC Investigates Meme Stocks
Picture
Yesterday, we talked about how the 5% inflation rate left investors unfazed. Yesterday's market optimism rolled over to today. The NASDAQ led the indices, finishing up +.35%. Some analysts predict that the rotation of value vs. growth may be coming to a close as we leave the “reopening” stage of our economy.

With little breaking news today, I reflected on the SEC’s decision to investigate meme stocks and how the current market structure allows more prominent wholesale traders to manipulate the price. The SEC is rightfully reacting to the new market paradigm. Chairman Gary Gensler has expressly noted his focus on “wholesalers,” the companies who process retail trader orders for profit. Most new generation brokerages, such as Robinhood and Webull, make their money by selling their users' orders to market makers such as Citadel, which gives those wholesalers the ability to move the market by combining the orders.  

​What's Up

Dick's Sporting Goods (DKS) and Best Buy (BBY) Are Solid Retailers with Undervalued Stocks 
One of my favorite Stock Card features is the ability to create and browse watchlists such as my 4-Greener watchlist. This watchlist gives me the list of companies that have high growth potential, solid operations, a history of overperforming the market, and are, for some reason, hovering in the undervalued price range.  Today,  two retailers grabbed my attention, Dick’s Sporting Goods (DKS) and Best Buy (BBY). 

Dick’s Sporting Goods (DKS) is a solid stock. Despite the company's solid upward movement since the pandemic hit, the stock is still in the undervalued range. It continues to open new stores and strengthen its eCommerce capabilities by allowing in-store and curbside pick-up. It's also quite impressive how the company acquired 8 million new customers and use its loyalty program to keep customers coming back for more. If you are a dividend-seeker, Dick's Sporting Goods could be a good one to consider. 

Like Dick's, Best Buy (BBY) has invested in its store experience and eCommerce capabilities. Both companies would inevitably put out an excellent performance in 2021 since investors are comparing the revenue and profit figures with 2020's dip when most retail operations were shut. Best Buy can be a good addition to a dividend-focused portfolio with its cash-generating operations and undervalued stock. I don't own either of the stock but may be researching them further to add to Stock Card's Dividend Seeker portfolio.


​What's Down

The 10% Drop in Vertex Pharmaceuticals (VRTX) May Mean a Buy-the-Dip Opportunity
Yesterday, things looked quite positive for Vertex Pharmaceuticals (VRTX). It announced that its gene-editing efforts to deal with diseases such as sickle-cell were showing signs of success. It had tested multiple patients, and the months of study proved conclusively that the treatment was effective. The optimism was short-lived though.

Today, Vertex shares dropped a whopping -10.96%. With such good news the day before, the drop came as a shock. The company has just discontinued the development of another drug, VX-864. Investors were expecting a breakthrough treatment for the genetic disorder AATD but instead were informed that its effectiveness was not evident during trials.

Despite today's drop, VRTX is still among the leading stocks that are researching and shaping the future of gene editing. Its stock price is undervalued and the company has a strong balance sheet to fund its future R&D effort. If you are an investor who can tolerate market fluctuations that come with FDA-related news, this may be a chance to buy the dip in VRTX. 

Want to receive this daily stock market recap report in your mailbox?

Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
Give Stock Card A Try!

Comments are closed.

    RSS Feed


    Archives

    December 2022
    September 2022
    July 2022
    February 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    January 2020
    October 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    Battle
    Education
    ETF Investing
    How To Invest
    New Podcast Episode
    New Portfolio
    Portfolio Update
    Starter 2020
    Stock Card VIP Pick
    Stock Lists
    The Daily Hype
    Update
    Watchlist Worthy
    Winners And Losers

© 2017 StockCard.io. All Rights Reserved.
​​
Disclaimer: StockCard.io is not, neither operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on StockCard.io and Stock Card Weekly represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The Stock Card team may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall StockCard.io be liable to any subscriber, visitor, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on StockCard.io, or relating to the use of, or inability to use, StockCard.io or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up